Modulation of neuroinflammation in glaucoma by GLP-1R agonist

Project Goals

Inflammation of the nervous system tissue contributes to blinding loss of nerve cells in the eye and brain in glaucoma. In this project, we aim to repurpose an existing FDA-approved drug to modify this inflammatory response with the goal of identifying a potential new therapy to help preserve vision in patients with glaucoma.

Project Summary

In our first specific aim, we will assess the effect of GLP-1R agonist on neuroinflammation throughout the visual pathway by quantifying myeloid cell activity with intraocular pressure (IOP) and glaucoma disease status in our unique large animal model. In our second aim, we will determine the effect of GLP-1R agonist on myeloid cell molecular profiles in the visual pathway using state-of-art single-cell transcriptomics approaches.

Publications

First published on: May 15, 2024

Last modified on: December 22, 2024